CLAIMS

1. A peptide consisting of the amino acid sequence:

$(R^1)_x$-P-$(R^2)_y$,

wherein:

P is an amino acid sequence having at least 90% identity to a sequence of SEQ ID NO:68;

R^1 is an amino acid sequence consisting of from 5 to 80 amino acids;

R^2 is an amino acid sequence consisting of from 5 to 80 amino acids; and

wherein x and y are not both zero.

2. The peptide of claim 1, wherein P is an amino acid sequence having at least 95% identity to a sequence SEQ ID NO:68.

3. The peptide of claim 1, wherein P is an amino acid sequence identical to a sequence of SEQ ID NO:68.

4. The peptide according to any one of claims 1 to 3, wherein x is one and y is zero.

5. The peptide according to any one of claims 1 to 3, wherein x is zero and y is one.

6. The peptide according to any one of claims 1 to 3, wherein x and y are both one.

7. The peptide according to any one of claims 1 to 3, wherein the peptide consists of from 26 to 100 amino acids.

8. The peptide of claim 7, wherein the peptide consists of from 26 to 50 amino acids.

9. The peptide of claim 7, wherein the peptide consists of from 25 to 26 amino acids.

10. A composition comprising a peptide according to any one of claims 1 to 9.

11. The composition of claim 10, wherein the composition is formulated for pharmaceutical administration.

12. The composition of claim 10 or 11, wherein the composition further comprises a second polypeptide, the second polypeptide consisting of the amino acid sequence:

$(R^1)_x$-P-$(R^2)_y$, wherein:

P is an amino acid sequence having at least 85% identity to at least nine consecutive amino acids of a sequence selected from SEQ ID NOS:10, 68, 159, 250, 344, 477, 568, 659, and 740;

R^1 is an amino acid sequence consisting of from 1 to 80 amino acids;

R^2 is an amino acid sequence consisting of from 1 to 80 amino acids; and

each of x and y are independently zero or one.

13. Use of a peptide of any one of claims 1-9 in the manufacture of a medicament for inducing an immune tolerance to FVIII in a subject.

14. Use of a composition of any one of claims 10-12 in the manufacture of a medicament for inducing an immune tolerance to FVIII in a subject.

15. The use according to claim 13 or claim 14, wherein the medicament is to be administered to prevent development of anti-FVIII antibodies in the subject.

16. The use according to claim 13 or claim 14, wherein the medicament is to be administered to reduce the amount of anti-FVIII antibodies present in the subject.

17. A method of making a peptide, the method comprising the steps of:

a) providing a culture of cells comprising a polynucleotide that encodes a peptide according to any one of claims 1 to 9; and

b) expressing the peptide in the culture of cells.

18. A method of identifying a FVIII peptide-specific T cell, the method comprising:

a) combining a plurality of CD4+ T cells with a peptide complexed with a MHC class II multimer, wherein the peptide is a peptide according to any one of claims 1 to 9;

and

b) identifying at least one of the members of the plurality of CD4+ T cells that is specific for the peptide complexed with the MHC class II multimer.

19. The method of claim 18, wherein the MHC class II multimer is a MHC class II tetramer.

20. The method of claim 18 or 19, wherein the peptide or MHC class II multimer further comprises a detectable moiety.

21. The method according to any one of claims 18 to 20, further comprising isolating the at least one CD4+ T cell that is specific for the peptide.

22. The method of claim 21, wherein the CD4+ T cell is isolated using flow cytometry.